On March 16, market sources indicated that BioMap, an AI-powered life sciences large model company co-founded by Baidu founder Robin Li, has submitted a listing application to the Hong Kong Stock Exchange, potentially raising several hundred million US dollars. Established in 2020 by Robin Li and former Baidu Ventures CEO Wei Liu, BioMap is positioned as an "AI + Life Sciences" infrastructure platform. Besides BioMap, several other AI-driven drug discovery firms are reportedly planning listings in Hong Kong. It is understood that METiS Pharmaceuticals, an "AI + delivery platform" company, is considering a Hong Kong IPO to raise approximately $200 million. Another notable entity is Earendil Labs, the overseas subsidiary of HuaShen AI, a Delaware-based "dark horse" company focused on AI-driven macromolecular innovative drug R&D, which is preparing for a Hong Kong listing with China International Capital Corporation (CICC) and Morgan Stanley, aiming to raise up to $500 million.
The clustering of IPOs by companies like BioMap and Earendil Labs in the first quarter of 2026 is not driven by a single factor but results from the convergence of improved market liquidity and a qualitative leap in industry commercialization validation. A wave of capital is heating up the AI drug discovery sector. From a market perspective, since the beginning of 2026, a rebound in global tech stocks has spurred a valuation recovery in Hong Kong's biopharmaceutical sector, providing a more favorable financing environment for AI drug discovery firms. This trend follows last year's recovery momentum. Public data shows that in 2025, the domestic AI drug discovery sector witnessed 32 financing events, with a total financing amount exceeding 6.7 billion yuan, a significant year-on-year increase of 130.5%. At the end of 2025, Insilico Medicine's successful listing, which saw its shares surge 45% on its debut, set a record for the largest biotech IPO on the Hong Kong stock market, opening capital market access for subsequent players.
More crucially, the industry itself has reached a qualitative turning point in commercialization validation. Many AI drug discovery companies have progressed from the early proof-of-concept stage to a new phase characterized by the batch advancement of clinical pipelines and the realization of platform-based commercial revenue. BioMap's xTrimo V4 life sciences large model is already involved in over 60 proof-of-concept projects, covering key areas such as novel target discovery, antibody design, and innovative drug R&D. Insilico Medicine boasts an innovative internal pipeline of over 27 preclinical candidate compounds, with 10 molecules having received clinical trial approvals. AI technology has extended from the front-end of drug discovery to the entire process, including clinical prediction and patient recruitment. Leveraging its Pharma.AI platform, the time from target discovery to preclinical candidate compound (PCC) identification has been reduced from the industry average of 4.5 years to 12-18 months, significantly enhancing R&D efficiency and reducing costs. According to a Sinolink Securities report, AI reduces new drug R&D costs and increases the return on R&D investment by fivefold. Furthermore, the commercial value of AI-discovered drugs is projected to be 20 times higher than standard drugs and 2.4 times higher than best-in-class precision medicines.
Simultaneously, AI drug discovery firms are beginning to generate commercial revenue through technology licensing and collaborative development. For instance, Insilico Medicine's MMAI Gym platform and its collaboration with Liquid AI are creating a second growth curve akin to a CXO "water seller," allowing capital markets to see a clear path from cash-burning to profitability. The combination of these three validations—technology, pipeline, and revenue—is the core driver behind this wave of IPOs.
The core valuation logic for non-profitable AI drug discovery firms in the current market is shifting its focus from the disruptiveness of the technology platform to the progress and data of clinical pipelines. In the early stages, valuations primarily relied on the disruptive potential of the technology platform. Examples include BioMap's xTrimo V4 life sciences large model with 268 billion parameters and XtalPi's global largest database of drug molecule quantum mechanics parameters. By demonstrating AI's advantages in areas like target discovery hit rates (reaching 16%-20%, far exceeding the traditional 0.1% benchmark) and molecular design efficiency, these companies gained favor with capital markets.
However, as the industry develops, investors have become more rational, and clinical pipeline data has become the core anchor for valuation. A Goldman Sachs research report notes that AI drug discovery has entered a phase of quantifiable financial value realization. Empirical analysis of 96 AI-designed drugs shows a significant improvement in early-stage clinical success rates, making clinical data a key differentiator for company valuation. Specifically, investors focus on three dimensions: first, the number and stage of pipelines (e.g., the proportion of Phase II/III projects); second, the quality of clinical data (e.g., safety, efficacy, superiority over existing therapies); and third, pipeline differentiation (e.g., targeting unmet clinical needs in areas like rare diseases and oncology).
Concurrently, platform commercialization capability has become an important value-add. This includes revenue from technology licensing, milestone payments from collaborative development, and premiums on CRO/CDMO contracts. Such revenue not only validates the technology's value but also provides companies with cash flow support, reducing reliance solely on financing. Therefore, the current valuation logic presents a tripartite structure: "clinical pipeline as the primary factor, supplemented by technology platform and commercialization capability," where clinical data is the core variable determining valuation levels. In the future, pure technology companies lacking clinical validation capabilities will be phased out. Leading companies will expand their advantages through mergers and acquisitions, further increasing industry concentration.
Capital attention is expected to form a "barbell" distribution: early-stage capital will focus on disruptive technology platforms, while later-stage capital will prefer companies with mature clinical data. Additionally, the capability for overseas licensing and establishing global clinical networks will become core valuation metrics, pushing the industry from domestic competition towards global competition.
In 2025, financing in China's AI drug discovery sector exhibited a structural divergence characterized by a slight decrease in the number of deals but a significant rebound in the total financing amount. Compared to previous years, capital flow has shifted from a "broad net casting" approach to "picking the best." On one hand, capital is highly concentrated in leading companies, with the top five firms approaching a 50% concentration rate, indicating a strengthening head effect. On the other hand, early-stage projects (Series B and earlier) accounted for over 70% of financing, with capital favoring high-quality enterprises possessing "closed-loop technological capability + commercialization validation."
These enterprises typically own proprietary generative AI platforms, have tangible pipeline outputs in small or large molecule fields, can secure high milestone payments and sales royalties from multinational pharmaceutical companies, and can empower the entire chain from target discovery to preclinical research.
For AI drug discovery firms queuing for IPOs, the current window of opportunity requires building a three-dimensional narrative strategy focusing on "technology + pipeline + ecosystem," balancing technological attributes with biopharmaceutical attributes to attract diverse long-term capital. First, strengthen the core narrative around clinical pipelines, letting the data speak. Emphasize key projects entering Phase II/III clinical trials, particularly those targeting unmet clinical needs (e.g., Insilico Medicine's ISM001-055 for idiopathic pulmonary fibrosis). Highlight the differentiated advantages of AI-designed drugs by comparing them with existing therapies. Simultaneously, disclose clinical data (such as safety data, efficacy trends) in detail to boost investor confidence.
Second, demonstrate the commercialization capability of the technology platform, rather than merely emphasizing technical advancement. For example, BioMap could highlight the validation results of its BioMap OS system across over 60 proof-of-concept projects and its revenue-sharing models with pharmaceutical partners. Insilico Medicine could emphasize the end-to-end capability of its Pharma.AI platform and the cash flow generated from technology licensing, allowing investors to see the path to monetizing technological value and reducing concerns about continuous fundraising.
Finally, construct a narrative of industrial ecosystem synergy. On one hand, emphasize the disruptive potential of AI technology for the biopharmaceutical industry (e.g., increased R&D efficiency, cost reduction) to attract technology growth capital. On the other hand, highlight collaborations with traditional pharma companies and CRO/CDMO firms (e.g., BioMap's strategic cooperation with a Hong Kong investment management company, Insilico Medicine's collaborations with Fosun Pharma and Sanofi) to demonstrate industry recognition and attract specialized biopharmaceutical investment institutions.
Furthermore, it is advisable for companies to clarify a dual-drive strategy of "platform + pipeline" before listing, retaining the high-growth potential of a tech company while being supported by the pipeline value of a biopharma company, thereby forming a differentiated competitive advantage and paving the way for attracting long-term capital.